<?xml version="1.0" encoding="UTF-8"?>
<p>Adoptive immunotherapy by means of donor leukocyte infusion has been used, curing HAdV infection, but carries the risk of developing graft versus host reactions. Therapies such as modified HAdV-specific T-cells are expensive and time consuming with complex administration procedures [
 <xref rid="B12" ref-type="bibr">12</xref>].
</p>
